These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 18500428)

  • 21. Combined plasma-exchange and immunosuppressive therapy for neurologic involvement of systemic lupus erythematosus.
    Marson P; Tenderini ML; Doria A; Rigoli AM; De Silvestro G
    Recenti Prog Med; 1994 Jan; 85(1):72-3. PubMed ID: 8184184
    [No Abstract]   [Full Text] [Related]  

  • 22. The B cell in systemic lupus erythaematosus: a rational target for more effective therapy.
    Driver CB; Ishimori M; Weisman MH
    Ann Rheum Dis; 2008 Oct; 67(10):1374-81. PubMed ID: 17720723
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Primary ascites as the presenting feature of systemic lupus erythematosus: response to cyclosporin therapy.
    Hernández Pérez J; Fernández Fernández J; Sanz Moreno C; Garrancho JM; Botella J
    Nephrol Dial Transplant; 1995; 10(8):1451-3. PubMed ID: 8538943
    [No Abstract]   [Full Text] [Related]  

  • 24. Rituximab treatment of pulmonary arterial hypertension associated with systemic lupus erythematosus: a case report.
    Hennigan S; Channick RN; Silverman GJ
    Lupus; 2008 Aug; 17(8):754-6. PubMed ID: 18625655
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treating lupus: from serendipity to sense, the rise of the new biologicals and other emerging therapies.
    Sousa E; Isenberg D
    Best Pract Res Clin Rheumatol; 2009 Aug; 23(4):563-74. PubMed ID: 19591785
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Improvement with rituximab in a patient with both rheumatoid arthritis and myasthenia gravis.
    Kerkeni S; Marotte H; Miossec P
    Muscle Nerve; 2008 Oct; 38(4):1343-5. PubMed ID: 18816604
    [No Abstract]   [Full Text] [Related]  

  • 27. Clinical outcome and B cell depletion in patients with rheumatoid arthritis receiving rituximab monotherapy in comparison with patients receiving concomitant methotrexate.
    Owczarczyk K; Hellmann M; Fliedner G; Röhrs T; Maizus K; Passon D; Hallek M; Rubbert A
    Ann Rheum Dis; 2008 Nov; 67(11):1648-9. PubMed ID: 18854518
    [No Abstract]   [Full Text] [Related]  

  • 28. Successful treatment with B-cell depleting therapy for refractory systemic onset juvenile idiopathic arthritis: a case report.
    Kasher-Meron M; Uziel Y; Amital H
    Rheumatology (Oxford); 2009 Apr; 48(4):445-6. PubMed ID: 19164423
    [No Abstract]   [Full Text] [Related]  

  • 29. Anti-S alloantibody underlying pan agglutinating autoantibody in a patient of systemic lupus erythematosus: a case report.
    Pahuja S; Sethi N; Gurtoo A; Kumar Pande A; Chaudhary P; Jain M
    Iran J Immunol; 2011 Mar; 8(1):58-63. PubMed ID: 21427497
    [No Abstract]   [Full Text] [Related]  

  • 30. Severe gastrointestinal involvement in systemic lupus erythematosus treated with rituximab and cyclophosphamide (B-cell depletion therapy).
    Waite L; Morrison E
    Lupus; 2007; 16(10):841-2. PubMed ID: 17895311
    [No Abstract]   [Full Text] [Related]  

  • 31. T-cell depletion improves outcome after autologous stem cell transplant in patients with systemic lupus erythematosus (SLE).
    Kamrava MR; Anderson EM; Kalunian K; Bashey A; Holman P; Medina B; Ball ED; Carrier E
    Bone Marrow Transplant; 2005 Jan; 35(2):205-6. PubMed ID: 15543199
    [No Abstract]   [Full Text] [Related]  

  • 32. Anti-CD20 treatment prolongs syngeneic islet graft survival and delays the onset of recurrent autoimmune diabetes.
    Hu C; Deng S; Wong FS; Wen L
    Ann N Y Acad Sci; 2008 Dec; 1150():217-9. PubMed ID: 19120299
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Macrophage activation syndrome as an early presentation of Lupus.
    McCann LJ; Hasson N; Pilkington CA
    J Rheumatol; 2006 Feb; 33(2):438-40. PubMed ID: 16482659
    [No Abstract]   [Full Text] [Related]  

  • 34. [Biological treatment of rare inflammatory rheumatic diseases].
    Baslund B
    Ugeskr Laeger; 2008 Jun; 170(24):2150-2. PubMed ID: 18565301
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Rheumatology 2010].
    Hermann W; Müller-Ladner U
    Dtsch Med Wochenschr; 2010 Jun; 135(25-26):1309-11. PubMed ID: 20556688
    [No Abstract]   [Full Text] [Related]  

  • 36. [Hoarseness in patient with systemic lupus erythematosus].
    Reiter R; Stier KH; Brosch S
    Laryngorhinootologie; 2011 Apr; 90(4):226-7. PubMed ID: 20799156
    [No Abstract]   [Full Text] [Related]  

  • 37. Less is more: the detrimental consequences of immunosuppressive therapy in the treatment of type-1 diabetes.
    Askenasy N
    Int Rev Immunol; 2015; 34(6):523-37. PubMed ID: 25793647
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunospecific therapy for type I diabetes mellitus.
    Culler FL; O'Connor R; Kaufmann S; Jones KL; Roth JC
    N Engl J Med; 1985 Sep; 313(11):695-6. PubMed ID: 3875034
    [No Abstract]   [Full Text] [Related]  

  • 39. [T cell subsets and the helper effect of T cells in rheumatoid arthritis and systemic lupus erythematosus, and the effects of antirheumatic agents (author's transl)].
    Kobayashi K; Ohno I; Negishi M; Ide H; Takahashi T
    Ryumachi; 1982 Feb; 22(1):28-37. PubMed ID: 6979802
    [No Abstract]   [Full Text] [Related]  

  • 40. Targeting B cells in the treatment of childhood-onset systemic lupus erythematosus.
    Huggins JL; Brunner HI
    J Pediatr; 2006 May; 148(5):571-3. PubMed ID: 16737861
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.